Lupin buys two brands from Sanofi in Europe, Canada
Mumbai: Lupin Limited, a global pharma major, today announced that Lupin Atlantis Holdings SA, the Company's European hub entity, has concluded the acquisition of two well-known brands, Aarane in Germany and Nalcrom in Canada and the Netherlands, along with the associated trademark rights, from Sanofi.
According to the release, the transaction aligns with Lupin's strategy to grow its global presence in Specialty areas, where the company has a leading position, with high-quality products that are innovative or unique in the market. This acquisition will enhance Lupin's Respiratory business in Germany, by aiding in the expansion of the newly established franchise, following the introduction of Luforbec.
Nalcrom (sodium cromoglicate Oral) belongs to a group of medicines called anti-allergics. It is used to treat food allergies after adequate testing for sensitivity to specific allergens in conjunction with restricting the main allergens.
Aarane (sodium cromoglicate/reproterol hydrochloride pressurized inhalation) is a chromone complex indicated in symptomatic acute treatment of sudden asthma attacks (e.g., allergic forms or those triggered by exertion, stress or infections) and targeted prevention of exercise-induced asthma or in cases of foreseeable allergen contact.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.